Protein-drug complexes important for immunoregulation and organ transplantation

Current Opinion in Structural Biology

Volumn 6, Issue 6, 1996, Pages 838-847

  Navia, Manuel A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; BREQUINAR; CALCINEURIN; CYCLOSPORIN A; DRUG BINDING PROTEIN; FK 506 BINDING PROTEIN; GLUCOCORTICOID; HYDROXYUREA; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; LEFLUNOMIDE; MERCAPTOPURINE; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHORYLASE; PREDNISONE; PRODRUG; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; TERIFLUNOMIDE;

DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; GRAFT REJECTION; HUMAN; IMMUNOREGULATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PURINE SYNTHESIS; REVIEW;

EID: 0030473342     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-440X(96)80015-7     Document Type: Article

References (48)

1. Halloran PF: Molecular mechanisms of new immunosuppressants. Clin Transplant 1996, 10:118-123.
2. Morris RE: Mechanisms of action of new imrnunosuppressive drugs. Kidney Inl Suppl 1996, 49:26-38. A lucid and comprehensive review of the field.
3. Dayton JS, Turka LA, Thompson CB, Mitchell BS: Comparison of the effects of mizoribine with those of azathioprlne, 6-mercaptopunne and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol P/iarmaco/1992, 41:671-676.
4. Hirschmann R: Medicinal chemistry in the golden age of biology: lessons from steroid and peptide research. Angew Chem /n(d1991, 30:1278-1301.
5. Cardenas ME, Zhu D, Heiiman J: Molecular mechanisms of immunosuppression by cycloaporine, FK50E and rapamycin. Curr Opin Nephrol Hypertens 1995, 4:472-477. This paper presents a summary of the known toxicities in molecular terms.
6. Morris RE: Mechanisms of action of new imrnunosuppressive drugs. Ther Drug Monit 1995, 17:564-569 A review article with extensive references to the historical background that emphasizes the serendipitous character of drug discovery and mechanism elucidation in the area of immunostippression.
7. Borel JF, Feuer C, Gubler HV, Stahelin H: Biological effects of cyclosporin A: a new antilymphocytic agent Agents Actions 1976, 6:468-475.
8. Allison AC, Eugui EM: Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Ctin Transplant 1996, 10:77-84. A well written review of the role of de noi/o purine biosynthesis in immunosuppressive therapy.
9. Nadler SG, Eversole ACB, Tepper MA, Cleavela/id JS: Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995, 17:700-703.
10. Cantrell D: T cell antigen receptor signal transduction pathways. Annu Rev Immunol 1996, 14:259-274. A comprehensive and unusually clear review of the T cell antigen receptor signal pathways.
11. Gilman AG, Rail TW, Nies AS, Taylor P: Goodman and Gilman's The Pharmacological Basis o! Therapeutics, edn 8. New York; Pergamon Press; 1990.
12. 2 Rosen J, Day A, Jones TK, Jones ETT, Nadzam AM, Stein RB: Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small molecule drug discovery, j Med Chem 1995. 38:4855-4871. An excellent and comprehensive review of intracellular signalling and control mechanisms, and of low molecular weight agents, both natural and synthetic, that have been found to influence them. This review includes a most helpful explanation of the overly cute, content-deprived, and otherwise unnecessarily confounding nomenclature that is so favored In the area of signal transduc tion.
13. Rastinejad F, Perlmann T, Evans RM, Sigler PB: Structural determinants of nuclear receptor assembly on DMA direct repeats. Nature 1995, 375:203-211.
14. Gewirth DT, Sigler PB: The basis for half-site specificity explored through a non-cognate steroid receptor-DNA complex. Nat Struct Bio! 1 995, 2:386-394
15. Schwabe JWR, Chapman L, Finch JT, Rhodes D: The crystal structure of the estrogen receptor DMA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 1993, 75:567-578.
16. 6. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, Murcko MA, Wilson KP: Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996, 85:921-930. The structure of IMPDH in complex with mycophenolic acid provides the necessary tools for structure-based drug design against de novo purine biosynthesis as a target for immunosuppression.
17. Davis JP, Cain GA. Pitts WJ, Magolda RL, Capeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996,35:1270-1273. On the basis of a definitive investigation of the properties of leflunomide, this brilliant study assembles a compelling argument in favor of de novo pyrimidine biosynthesis-and its interruption by dihydroorotate dehydroge-nase inhibitors-as the next target of opportunity for the design of novel immunosuppressive agents.
18. B. Makov.'ka L, Sher LS, Cramer DV: The development of brequinar as an immunosuppressive drug for transplantation. Immunol Rev 1993, 136:51-70.
19. Xu X, Williams JW, Gong H, Finnegan A, Chong AS: Two Activities of the immunosuppressive metabolite of leflunomide A771706. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996, 52:527-534.
20. Ealick SE, Babu YS, Bugg CE, Erion MD, Guida WC, Montgomery JA, Secrist JA III: Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors. Proc Wart /lead Sei USA 1991, 88:11540-11 544.
21. Liu J, Farmer JD Jr, Lane WS, Fnedman J, Weissman l, Schreibet SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815
22. Navia MA, Chaturvedi PR: Design principles for orally bioavailable drugs. Drug Discovery Today 1996, 1:179-189, A systemattzation of the elements that affect the oral bioavailability of drugs, and their incorporation into the drug design process, is presented. This paper includes an analysis of the molecular weight distribution of all marketed drugs.
23. Armistead DM, Badia MC, Deininger DD, Duffy JP, Saunders JO, Tung RD, Thomsom JA, DeCenzo MT, Futer O. Livingston DJ e; ai: Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystrailogr D 1995, 51:522-528. See annotation [24*].
24. Dragovich PS, Barker JE, Frech J, Imbacuan M, Kalisj VJ, Kissinger CR, Kmghton DR, Lewis CT, Moomaw EW, Parge HE et al.: Structure-based drug design of novel, urea-containing FKBP12 inhibitors. J /Werf Chem 1996, 39:1872-1884 These two papers ([23,241) both include a short review and discussion of the published results on nonimmunosuppressive FKBPl2-binding ligands.
25. Crabtree GR, Clipstone NA: Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu Rev Biochem 1994, 63:1045-1083.
26. Rao A: NF-ATp: a transcription factor required for the coordinate induction of several cytokine genes. Immunol Today 1994, 15.274-280.
27. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, FiUgibbon MJ, Fleming MA, Caron PR, Hsiao K, Navia MA: Xray structure of calcineurin inhibited by the immunophilin immunosuppressant FKBP12 - FK50E complex. Ce/7 1995, 82:507-522. The structure of the calcineurin-FKBP12-FK506 complex first demonstrated that the inhibition of phosphatase activity associated with FK506 binding was indirect
28. Kissinger CR, Parge EH, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, Moomaw EW ef a!.: Crystal structure of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 1995, 378:641-644.
29. Mikol V, Kallen J, Ptlugl G, Walkinshaw WID: X-ray structure of a monomeric cyclophilin A-cyciosporin A crystal complex at 2.1 A resolution. J Mo! Bio! 1993, 234:1119-1130.
30. Lohse DL. Denu JM, Dixon JE: Insights derived from the mm structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. Structure 1995, 3:987-990. An excellent review of the similarities and differences in structure across the Ser/Thr phosphatase class.
31. Barford D: Protein phosphatases. Curr Opin Struct Biol 1995, 5:728-734. An important and profoundly scholarly review ol a complicated area that has clarified the field for the rest ol us.
32. Kirn EE, Baker CT. Dwyer MD, Murcko MA, Rao BG, Tung RD, Navia MA: Crystal structure of HIV 1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995, 117:1181-1182.
33. Remuzzi G, Penco N: Cydosporine induced renal dysfunction in experimental animals and humans. Kidney Int Supp/1995, 48:70-74.
34. Su Q, Weber L, Le Hir M, Zenke G, Ryffel B: Nephrotoxicity of cyclosporin A and FK5U6: inhibition of calcineurin phosphatase. Renal Physiol Biochem 1995, 18:1 28-139. This paper reviews the physiological basis for the nephrotoxicity associated with calcineurin inhibition.
35. Dumonl FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS. Harrison R. Sewell T, Kindt VM, Beattie TR, Wyvratt M, Sigal NH: The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992, 176:751 -760
36. Backer JW, Rotonda J, McKeever BM, Chan HK, Marcy AI, Wiederrecht Q. Hermes JD, Springer JP: FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Crtem 1993, 268:11335-11339.
37. Dument FJ, Su Q: Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996, 58:373-395. An exposition ol the current understanding of rapamycin structure and function.
38. Levitzki A: Signal-transduction therapy: a novel approach to disease management Eur J Biochem 1994, 226:1-13.
39. Abraham RT, Wiederrecht GJ: Immunopharmacology of rapamycin. Annu Rev Immunoi 1996, 14:483-510.
40. Proud CG: p70 S6 kinase; an enigma with variations. Trends Biochem Sei 1996, 21:181-185.
41. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J: Atomic structures of human immunophilin FKBP12 complexes with FK506 and rapamycin. J Mol Brol 1993, 229:105-124.
42. Choi J, Chen J, Schreiber SL, Clardy J: Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1994, 273:239-242.
43. Lori F, Malykh A, Cara A, Sun D, Weinslein J, Lisziewicz J, Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994, 266:801-805.
44. Lori F Gallo RC: Hydroxyurea and AIDS: an old drug finds a new application? AIDS Res Hum Retroviruses 1996, 11:1149-1151. An insightful review ol a new and exciting therapeutic opportunity for use in the control of AIDS.
45. Ichimura H, Levy JA: Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995, 211:554-560. A synthesis across disparate fields that deserves far more attention than it has received.
46. Wainberg MA, Dascal A, Blain N, Filz Gibbon L, Boulerice F, Numazaki K, Tremblay W: The effect of cyclosporin A on infection of susceptible cells by human immunodeficiency virus. Blood 1988, 72.1904-1910.
47. Malkovsky M, Rich DH, Bartz SR: Immunodeficiency virus inhibitory effects of cyclosporine and its nonimmunosuppressive analogs. Int Antiviral News 1996, 4:7-9.
48. Billich A, Hammerschrnid F, Peichl R Wenger R, Zenke G, Quesinaux V, Rosenwirth B: Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporine analog with activity against human immunodeficiency virus type-1 (HIV-1): interference with HIV protein-cyclophilin A interactions, j Viral 1995.69:2451-2461. An excellent example of the kind of exciting cross-fertilization across broadly disparate areas that can take place within trie pharmaceutical industry when at its best.